Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses

Effects of intravenous terbutaline on heart rate, arterial pressure and blood gases in anesthetized horses breathing air

OBJECTIVE

To investigate the effects of intravenous (IV) administration of terbutaline on PaO₂, PaCO₂, pH, heart rate (HR) and arterial pressures in healthy, laterally recumbent horses breathing ambient air under total intravenous anesthesia (TIVA).

STUDY DESIGN

Prospective experimental study.

ANIMALS

Eight healthy adult horses were enrolled. Six horses, four mares and two geldings weighing 433-624 kg, completed the study.

METHODS

Horses were sedated with xylazine (1.0 mg kg^-1) IV for placement of arterial and venous catheters. Anesthesia was induced with midazolam (0.1 mg kg^-1) and ketamine (2.2 mg kg^-1) IV and maintained with an IV infusion of guaifenesin (50 mg mL^-1), ketamine (2 mg mL^-1) and xylazine (0.5 mg mL^-1) at 1.9 ± 0.3 mL kg^-1 hour^-1. Horses were in left lateral recumbency and breathed air spontaneously. Arterial blood was collected for pH and blood gas analysis during xylazine sedation, 15 minutes after induction of anesthesia, immediately before and 5, 15 and 30 minutes after administration of terbutaline (2 μg kg^-1), and when the horse was standing after recovery from anesthesia. HR, systolic (SAP), mean (MAP) and diastolic (DAP) arterial pressures were recorded at 5 minute intervals during anesthesia. Normal data were analyzed with anova and non-normal data were analyzed with a Friedman test with a p < 0.05 considered significant.

RESULTS

The mean PaO₂ decreased from baseline to <60 mmHg (8.0 kPa) during anesthesia (p < 0.0001) and did not improve after administration of terbutaline. After terbutaline administration, HR increased (p = 0.002), and SAP, MAP and DAP decreased (p < 0.001) with the greatest changes occurring immediately after terbutaline administration.

CONCLUSIONS AND CLINICAL RELEVANCE

Terbutaline (2 μg kg^-1) IV did not improve PaO₂ and was associated with adverse cardiovascular effects during TIVA in healthy, laterally recumbent horses breathing air.

Efficacy of Inhaled Levalbuterol Compared to Albuterol in Horses with Recurrent Airway Obstruction

Background

The (R)‐enantiomer of racemic albuterol (levalbuterol) has bronchodilatory properties whereas the (S)‐enantiomer causes adverse effects in human airways, animal models, and isolated equine bronchi. Levalbuterol is commercially available and improves pulmonary function of asthmatic patients with a longer duration of effect than albuterol.

Objective

To determine the dose at which inhaled levalbuterol produces maximal bronchodilatory effect (EDmax) and determine its duration of action in recurrent airway obstruction (RAO)‐affected horses in comparison to racemic albuterol.

Animals

Nine horses with inducible and reversible RAO.

Methods

Randomized, crossover trial. Horses were challenged with moldy hay to induce airway obstruction. Horses were treated with nebulized albuterol or levalbuterol chosen randomly. Pulmonary function testing (PFT) was measured before and for up to 3 hours after bronchodilatation challenge. Maximum change in transpulmonary pressure (DP_max) was measured to assess the dose effect and duration of action of each drug. After a 24 hours washout period, the bronchodilatation challenge was repeated with the second bronchodilator.

Results

The duration of effect was 60 minutes for albuterol and 120 minutes for levalbuterol. The dose of bronchodilator EDmax was not significantly different between albuterol and levalbuterol (EDmax = 125.0 [125–125 μg] and EDmax = 188 [125–188 μg] respectively; P = .068). The magnitude of bronchodilatation was not significantly different between the 2 treatments (61.1 and 59.9% decrease in DP_max for albuterol and levalbuterol respectively; P = .86).

Conclusions and clinical importance

Levalbuterol is as effective a bronchodilator as albuterol; although levalbuterol lasts twice as long as albuterol, its duration of action is still too short to make it practical for RAO treatment.

Pharmacokinetics of procaterol in thoroughbred horses

Procaterol (PCR) is a beta-2-adrenergic bronchodilator widely used in Japanese racehorses for treating lower respiratory disease. The pharmacokinetics of PCR following single intravenous (0.5 μg/kg) and oral (2.0 μg/kg) administrations were investigated in six thoroughbred horses. Plasma and urine concentrations of PCR were measured using liquid chromatography-mass spectrometry. Plasma PCR concentration following intravenous administration showed a biphasic elimination pattern. The systemic clearance was 0.47 ± 0.16 L/h/kg, the steady-state volume of the distribution was 1.21 ± 0.23 L/kg, and the elimination half-life was 2.85 ± 1.35 h. Heart rate rapidly increased after intravenous administration and gradually decreased thereafter. A strong correlation between heart rate and plasma concentration of PCR was observed. Plasma concentrations of PCR after oral administration were not quantifiable in all horses. Urine concentrations of PCR following intravenous and oral administrations were quantified in all horses until 32 h after administration. Urine PCR concentrations were not significantly different on and after 24 h between intravenous and oral administrations. These results suggest that the bioavailability of orally administrated PCR in horses is very poor, and the drug was eliminated from the body slowly based on urinary concentrations. This report is the first study to demonstrate the pharmacokinetic character of PCR in thoroughbred horses.